title: Overexpression of SYF2 correlates with enhanced cell growth and poor prognosis in human hepatocellular carcinoma.
abstract: SYF2, also known as p29/NTC31/CBPIN, encodes a nuclear protein that interacts with Cyclin D-type binding-protein 1. SYF2 has been reported to be involved in pre-mRNA splicing and cell cycle regulation. In the present study, we observed that SYF2 was obviously upregulated in HCC tumor tissues and cell lines, and its level was positively correlated with the tumor grade and Ki-67 expression, as well as poor prognosis of HCC. In vitro, using serum starvation-refeeding experiment, our results suggested that SYF2 was upregulated in proliferating HCC cells, and was positive correlated with the expression of PCNA and Cyclin D1. In addition, depletion of SYF2 decreased PCNA and Cyclin D1 levels. Accordingly, interference of SYF2 resulted in cells cycle arrest at G1/S phase in Huh7 HCC cells. Furthermore, we found that SYF2 might interact with Cyclin D1 and could confer doxorubicin resistance in HCC cells. These findings revealed that SYF2 might play a regulatory role in the proliferation of HCC cells. In summary, SYF2 may be a novel prognostic marker and serve as a potential therapeutic target in HCC.
authors.affiliation: Department of Digestion, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Shusen
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The Second People's Hospital of Nantong, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Weidong
authors.initials: W
authors.lastname: Shi
authors.affiliation: Class 5 Grade 13, Clinical Medicine, Medical College, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Yuyan
authors.initials: Y
authors.lastname: Chen
authors.affiliation: Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Zhiwei
authors.initials: Z
authors.lastname: Xu
authors.affiliation: Jiangsu Province Key Laboratory for Inflammation and Molecular Drug Target, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Jia
authors.initials: J
authors.lastname: Zhu
authors.affiliation: Department of Digestion, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Tingting
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Digestion, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Huang
authors.affiliation: Department of Digestion, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China.
authors.forename: Runzhou
authors.initials: R
authors.lastname: Ni
authors.affiliation: Department of Digestion, Affiliated Hospital of Nantong University, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China. ntluch@163.com.
authors.forename: Cuihua
authors.initials: C
authors.lastname: Lu
authors.affiliation: Department of Oncology, The Second People's Hospital of Nantong, Nantong University, Nantong, 226001, Jiangsu, People's Republic of China. xiubingzhang@163.com.
authors.forename: Xiubing
authors.initials: X
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D019938:Cyclin D1 / Q000378:metabolism; D004317:Doxorubicin / Q000494:pharmacology; D019008:Drug Resistance, Neoplasm; D005260:Female; D059585:G1 Phase Cell Cycle Checkpoints; D015972:Gene Expression Regulation, Neoplastic; D056945:Hep G2 Cells; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D034622:RNA Interference; D016601:RNA-Binding Proteins; D015398:Signal Transduction; D016019:Survival Analysis; D013997:Time Factors; D014162:Transfection; D015854:Up-Regulation; D055815:Young Adult
chemical_list: D000903:Antibiotics, Antineoplastic; D014408:Biomarkers, Tumor; C530104:CCND1 protein, human; C418608:GCIP-interacting protein p29, human; D009687:Nuclear Proteins; D018809:Proliferating Cell Nuclear Antigen; D016601:RNA-Binding Proteins; D019938:Cyclin D1; D004317:Doxorubicin
keywords: Cell proliferation; Cyclin D1; Hepatocellular carcinoma; Prognosis; SYF2